Aptadir

Executive Summary

Aptadir is an Italian biotech startup founded in 2019, specializing in aptamer-based RNA therapeutics to reprogram DNA methylation for treating diseases. Its platform selectively inhibits DNMT1, enabling targeted gene expression modulation. Initially focusing on Myelodysplastic Neoplasms (MDS) and other cancers, Aptadir aims to address intractable conditions with high unmet medical need. The company's approach leverages foundational research in epigenetics and aptamer technology to offer a novel therapeutic modality. As a preclinical-stage company, Aptadir has not yet disclosed specific pipeline milestones or funding rounds. Its success hinges on validating its platform in vivo, advancing toward IND-enabling studies, and securing partnerships or financing. The epigenetics field is gaining traction, but Aptadir faces competition from other epigenetic therapies and the inherent risks of early drug development. If successful, its technology could be broadly applicable across oncology and beyond.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical proof-of-concept study in MDS models45% success
• H1 2027IND filing for lead aptamer candidate30% success
• 2026Series A financing or strategic partnership25% success